Abstract:Abstract Background: Glioblastoma (GBM) is the most common and aggressive form of brain tumor, characterized by a poorly accessible microenvironment that render it notoriously hard to treat. The insufficient treatment success is, in large parts, due to its tremendous molecular heterogeneity, which affects the overall prognosis and response to therapies. The significant intra- and inter-tumor microenvironment (TME) composition heterogeneity plays a crucial role in GBM progression. Mostly due to this high, multifactorial immunosuppression occurring in the microenvironment, the efficacy of immunotherapy in GBM is low. Focusing on characterizing the components of different TMEs to evaluate their molecular and cellular component heterogeneity has a significant advantage to target group of cancer patients that would normally be resistant to immunotherapy. Methods: Deep spatial transcriptomics profiling was performed on non-treated glioblastoma human tissue microarrays (TMA) using NanoString's GeoMx Digital Spatial Profiler (DSP). 6 tumor tissues from 6 different patients were hybridized and analyzed with the Whole Transcriptomic Atlas (WTA) panel that includes 18,000 genes. Three regions of interest (ROIs) were selected per tissue sample. All the statistical analysis were performed with GeoMx® DSP Analysis Suite. Cell deconvolution using the SpatialDecon® algorithm (Nanostring®) was then performed to estimate mixed cell type abundance in the spatially-resolved gene expression defined segments. Results: Spatial transcriptomic analyses revealed that glioblastoma tumors varied dramatically in their global gene expression profiles and suggested the existence of differential gene expression among the tumors highlighting the inter-tumors heterogeneity of glioblastoma. Interestingly, different areas of the same tumor did not display distinct molecular profiles. Upregulation of stromal collagen genes was significantly detected in some patient specifically the fibrillar collagens type I, III and VI. Those findings indicated excessive collagen depositions in the surrounding of the tumor for some patient characteristic of tumor progression and involvement of cancer associated fibroblasts (CAFs) in the dysregulated collagen turnover leading to tumor fibrosis. Conclusion: As a cold tumor, malignant glioma has strong immunosuppression and immune escape characteristics. The TME provides the “soil” for the survival of malignant tumors, and recent studies have highlighted a major role for cancer-associated fibroblasts (CAFs) in promoting immunotherapy resistance by excluding T cells from tumors in the TME. Here the spatial transcriptomic analyses allowed a better phenotypical stratification of the cancer patient. In some, targeting CAFs would improve the TME and enhance the efficacy of immunotherapy. Citation Format: Sandra Delebecq, Adele Ponzoni, Richard Ruez, Corinne Ramos, Jonathan Stauber. Heterogeneity in glioblastoma tumor microenvironment: Opportunities for new therapies. [abstract]. In: Proceedings of the American Association for Cancer Research Annual Meeting 2023; Part 1 (Regular and Invited Abstracts); 2023 Apr 14-19; Orlando, FL. Philadelphia (PA): AACR; Cancer Res 2023;83(7_Suppl):Abstract nr 4629.

Abstract 6171: Evolution of the spatial myeloid-lymphoid engagement in glioblastoma under temozolomide treatment

Abstract 3763: Comparative spatial analyses of the tumor immune landscape in different mouse models of glioblastoma

Abstract 4629: Heterogeneity in glioblastoma tumor microenvironment: Opportunities for new therapies

Abstract 1151: Reconstruction of the spatial ecosystem of glioblastoma reveals relationships between tumor cell states and microenvironment

Abstract 5496: Multi-omic spatial analysis of the tumor microenvironment in gliomas

116 Deep high-plex spatial phenotyping of glioblastoma multiforme provides new insights into the immune landscape and tumor heterogeneity

Abstract 5666: Exploring spatially resolved intra-tumoral heterogeneity of glioblastoma and neuronal mechanisms facilitating brain invasion

Abstract 5482: Spatial and multi-omic interrogation of the primary and recurrent glioblastoma microenvironment

Abstract 2125: Towards a spatial view of immune cell function in cancer

Abstract 3875: Glioblastoma mutational profiles drive cancer cell signaling and immune evasion

Abstract 3764: Spatially resolved immune landscape revealed sex-biased T-cell infiltration in glioblastoma

Spatial Profiling of Glioblastoma Microenvironments and Response to Immunotherapy

Abstract 2781: GBM cells mimic regulatory T cell function to protect the CSC pool from immune surveillance in recurrent GBM

Abstract B009: GBM cells mimic regulatory T cell function to protect the CSC pool from immune surveillance in recurrent GBM

Single-cell RNA sequencing reveals evolution of immune landscape during glioblastoma progression

Abstract PR014: Multiregion biopsies and corresponding neurosphere cultures reveal spatial divergence in glioblastoma evolution

Abstract 669: Immunophenotyping of Human Brain Tumors Reveals Myeloid Cell Mediated Anti-Glioma Axis

Abstract 4703: Applying spatial omics and computational integrative analyses to study drug responses and cancer immune cell interactions

Spatial Distribution of Immune Cells in Primary and Recurrent Glioblastoma: A Small Case Study

Abstract 3766: Utilizing whole-transcriptome digital spatial profiling for glioblastoma clinical biomarker discovery

Glioblastoma-instructed microglia transition to heterogeneous phenotypic states with phagocytic and dendritic cell-like features in patient tumors and patient-derived orthotopic xenografts